slides · global inventory
47 Quick Win Big Bet
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 9,718
Current window 4,861-4,890
Pages 324
Rows per page 30
Loop
4,861-4,890 of 9,718
14
The slide uses a three-column layout to present distinct growth pillars with associated quantitative targets.Apollo Global Management | Investor Presentation Deck | 38 slides · Apollo Global Management
Conference presentation Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
16
The table calculates the addressable patient population by filtering total incidence down to R/R incidence, then applying PRAME positivity and HLA-A*02:01+ prevalence.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
17
Immatics | Results Presentation Deck | 25 slidesImmatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
18
The slide uses a process flow diagram to illustrate clinical trial progression.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
35
The pillars are presented as a set of icons with descriptive text below each.Kinnevik | Investor Event Presentation Deck | 40 slides · Kinnevik
Conference presentation Investor relations Beat · VisualizationLoop · Quick Win Big Bet1 hit
36
Kinnevik | Investor Event Presentation Deck | 40 slidesKinnevik | Investor Event Presentation Deck | 40 slides · Kinnevik
Conference presentation Investor relations Beat · VisualizationLoop · Quick Win Big Bet1 hit
06
The slide uses a comparison frame to illustrate the mechanism of action for the drug candidate.Larimar Therapeutics | Investor Presentation Deck | 32 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
22
The slide provides a financial breakdown of assets as of August 31, 2021, including a disclaimer about FMV.Limoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
23
The slide highlights the strategic value of water rights as a tangible asset class.Limoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
24
Limoneira | Investor Presentation Deck | 39 slidesLimoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
25
Limoneira | Investor Presentation Deck | 39 slidesLimoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
26
Slide 26 of the deck.Limoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
20
Clinical trial design diagram showing randomization into three arms with specific drug regimens over a 10-week period.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
21
The slide uses a chevron-based timeline to illustrate the lifecycle management strategy.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
08
The slide serves as a title or introductory page for a specific drug candidate.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
09
Includes definitions of acronyms and citations for preclinical studies.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
10
Study methodology involves 10-week treatment on high fat/fructose/CHO diet.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
11
Study design timeline included; statistical significance noted for treatment groups.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
12
Includes definitions for abbreviations and source citations.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
13
NASH (Non-Alcoholic Steatohepatitis); NAFLD (Non-Alcoholic Fatty Liver Disease); T2DM (Type 2 Diabetes Mellitus); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
14
Company branding slide for a specific drug candidate.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
15
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of oxyntomodulin.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
16
Data from preclinical study in HF-DIO mice.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
17
The slide highlights that DA-1726 efficacy is likely due to dual GLP1R/GCGR agonism.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
18
Study uses male DIO-NASH mice with 30-week GAND feeding and 9-week treatment regimen.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
19
Includes study methodology timeline and statistical significance markers.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
20
NASH (Non-Alcoholic Steatohepatitis); MAD (Multiple Ascending Dose); SAD (Single Ascending Dose); PK (Pharmacokinetic); PD (Pharmacodynamic); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
21
Silo Pharma | Investor Presentation Deck | 24 slidesSilo Pharma | Investor Presentation Deck | 24 slides · Silo Pharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
22
The table highlights SiloPharma's unique 505(b)(2) regulatory pathway compared to peers.Silo Pharma | Investor Presentation Deck | 24 slides · Silo Pharma
Pitch deck Investor relations Beat · FinancialsLoop · Quick Win Big Bet1 hit
23
Silo Pharma | Investor Presentation Deck | 24 slidesSilo Pharma | Investor Presentation Deck | 24 slides · Silo Pharma
Pitch deck Investor relations Beat · FinancialsLoop · Quick Win Big Bet1 hit